News
Influenza drug to undergo “fast track” assessment by NICE
BMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7207.400 (Published 14 August 1999) Cite this as: BMJ 1999;319:400- Judy Jones
- BMJ
The influenza drug zanamivir (Relenza) will undergo “fast track” appraisal by the new National Institute for Clinical Excellence (NICE), which will recommend which treatments should be available on the NHS in England and Wales. Zanamivir is said to moderate the symptoms of flu and shorten bouts of the illness.
Professor Sir Michael Rawlins, the institute's chairman, said last week that he hopes to publish recommendations on the use of the drug this autumn. Thereafter, the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.